Sign Up
Stories
4DMT Presents Positive Interim Data
Share
Advancements in Cancer Treatment and Mar...
Advancing ALS Treatment through Protein ...
Biopharmaceutical Companies Merge and Pr...
4D Molecular Therapeutics Raises $300 Mi...
Biopharma Innovator GeNeuro Discloses Pr...
Biotech Collaboration for Industry Innov...
Overview
API
4D Molecular Therapeutics presents positive interim data for 4D-150, a potential intravitreal therapeutic for wet age-related macular degeneration. The company aims to disrupt the current treatment paradigm and seeks expedited Phase 3 development plans with regulatory designations.
Ask a question
How could the company's focus on genetic medicines in ophthalmology and pulmonology influence the future of medical treatments?
How might the potential intravitreal therapeutic impact the current treatment paradigm for wet age-related macular degeneration?
What are the implications of 4D-150's potential in reducing treatment burden for patients?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage